Ovarian Cancer Research Alliance Community Partner

RSS News

  • ALKS 4230-Keytruda Combo Found to Reduce Tumor Size, Halt Disease Progression November 24, 2020
    The combination of Keytruda (pembrolizumab) and ALKS 4230 was able to halt disease progression and reduce tumor size in a small group of heavily pre-treated patients with advanced ovarian cancer, according to data from an ongoing Phase 1/2 trial. Findings from the trial, called ARTISTRY-1 (NCT02799095), also showed the combination therapy had a manageable safety […]
  • Study to Examine if Blood Test Can Detect Cancer Early in Low-Risk Women November 19, 2020
    The University of Texas’ MD Anderson Cancer Center, in collaboration with the National Cancer Institute and Golfers Against Cancer, is evaluating the usefulness of a blood test called CA-125 at detecting ovarian cancer at early stages in low-risk women. Cancer antigen 125 (CA-125) is a protein found at higher levels in people with ovarian and other types of cancer. […]
  • ImmunoGen Teams Up With Huadong Medicine to Develop Mirvetuximab in China November 17, 2020
    ImmunoGen has announced a collaboration with Hangzhou Zhongmei Huadong Pharmaceutical Co, a subsidiary of Huadong Medicine, to develop and commercialize the ovarian cancer treatment mirvetuximab soravtansine to patients in China, Hong Kong, Macau, and Taiwan. The partnership will combine ImmunoGen’s expertise in cancer medication development with Huadong Medicine’s familiarity with regulatory agencies and connections to […]
  • CA125 Blood Test Useful in Diagnosing Ovarian Cancer in Routine Setting November 12, 2020
    A blood test measuring levels of the protein cancer antigen 125 (CA125) can help detect ovarian cancer in a primary care setting with considerable accuracy, a study reported. The research also showed for a first time that this test can also help in identifying other cancer types, particularly in women ages 50 and older. The […]
  • Lynparza Combo Approved in EU as First-line Maintenance for Advanced Ovarian Cancer November 10, 2020
    The European Commission has approved Lynparza (olaparib), in combination with bevacizumab, as a first-line maintenance therapy for women with advanced ovarian cancer positive for homologous recombination deficiency (HRD) and who responded to platinum-based chemotherapy. This indication also includes patients with advanced fallopian tube cancer or primary peritoneal cancer. Eligible HRD-positive tumors are those carrying mutations in […]
  • First Patient Dosed in Phase 2 Study of Cancer Vaccine Combination in Ovarian Cancer November 5, 2020
    The first patient has been dosed in a Phase 2 extension study investigating the cancer vaccine DSP-7888 (ombipepimut-S) in combination with the checkpoint inhibitor Keytruda (pembrolizumab), in people with platinum-resistant ovarian cancer. The announcement follows promising data from the first portion of this Phase 1b/2 clinical trial (NCT03311334). The Phase 2 part is actively recruiting […]
  • Zejula Approved in Europe as Maintenance Therapy for Advanced Ovarian Cancers November 3, 2020
    The European Commission has approved Zejula (niraparib) as a first-line maintenance therapy for people with advanced ovarian, fallopian tube, or primary peritoneal cancer, who respond to platinum-based chemotherapy. This decision follows a positive recommendation issued by the Committee for Medicinal Products for Human Use (CHMP), a branch of the European Medicines Agency (EMA). Zejula is now […]
  • 3 Companies Join Forces to Test Personalized ‘Teaching’ Vaccine for Ovarian Cancer October 29, 2020
    TransGene, NEC, and BostonGene have entered a strategic collaboration to test TG4050, an investigational personalized vaccine that aims to treat ovarian and head and neck cancers, according to a press release. TG4050 is an individualized therapy that stimulates a patient’s immune system into attacking cancer cells by “teaching” it which cells are malignant — based on the […]
  • Pilot Study Grants Available for Ovarian Cancer Research October 27, 2020
    Under its Pilot Study Awards program, the Rivkin Center is funding innovative research projects that seek to expand current knowledge about ovarian cancer, the non-profit has announced. Awarded grants will provide up to $75,000 over two years for studies involving newer ideas that are not yet widely accepted, and for those whose results are expected […]
  • FDA Places PC14586, for Cancers with Mutant Protein, on Fast Track October 22, 2020
    The U.S. Food and Drug Administration (FDA) has granted fast track designation to PC14586 as a potential treatment of advanced cancers that harbor a specific mutation affecting the protein p53, which includes some ovarian cancers. Fast track is given to support therapies with the potential to fill a serious unmet medical need. They are eligible […]
  • Phase 1 Trial of SL-172154 in Treating Advanced Ovarian Cancer Opens October 20, 2020
    Shattuck Labs has opened a Phase 1 clinical trial to investigate its lead candidate, SL-172154, in treating people with advanced ovarian cancer, the company announced in a press release. The trial (NCT04406623) is recruiting up to 33 patients at three sites in the U.S.: the John Wayne Cancer Institute at Providence St. John’s Health Center in California, […]
  • First Trial in New NCI-Zenith Partnership Will Test ZEN-3694 Combo for Resistant OC October 15, 2020
    The first clinical trial resulting from a new Zenith Epigenetic collaboration with the National Cancer Institute (NCI) will soon test a combination of the investigational therapy ZEN-3694 plus the immune checkpoint inhibitors Opdivo (nivolumab) and Yervoy (ipilimumab) for the treatment of resistant ovarian cancer. The new partnership was developed to test ZEN-3694 across several cancer indications. For this upcoming […]
  • OCRA Partners With Microsoft AI Initiative to Accelerate Ovarian Cancer Research October 13, 2020
    The Ovarian Cancer Research Alliance (OCRA) has partnered with Microsoft‘s AI for Health initiative, with the ultimate goal of accelerating ovarian cancer research using data science and artificial intelligence (AI). AI is a broad term that encompasses any use of a computer to accomplish tasks, from sorting to making complex decisions, that are usually associated […]
  • Lab-Grown 3D Tumor Model Provides New Tool to Study Ovarian Cancer, Treatments October 8, 2020
    A lab-grown, three-dimensional (3D) ovarian tumor model will give researchers a new way to study tumor growth in ovarian cancer and to test how tumors might respond to treatments, scientists say. The proof-of-concept study, “Peptide-protein coassembling matrices as a biomimetic 3D model of ovarian cancer,” was published in the journal Science Advances. Preclinical studies of […]
  • Lynparza Lowers Risk of Disease Progression in Advanced Ovarian Cancer, 5-year Data Show October 6, 2020
    When used as a first-line therapy to treat newly diagnosed women with advanced ovarian cancer who previously responded to platinum-based chemotherapy, Lynparza (olaparib) prolonged the time they lived without showing signs of disease progression compared to a placebo, according to five-year data from a Phase 3 trial. Updated findings from the study, called SOLO-1 (NCT01844986), were presented […]